ADA 2026 Day 3: Retatrutide TRIUMPH-4 Sets 28.7% Weight Loss Record With 75.8% Knee Pain Relief, Zenagamtide Delivers 14.6% Weight Loss and 89% A1C Target in Type 2 Diabetes Phase 2, CagriSema Brain Activity Data Reveals Appetite-Circuit Mechanism — June 7, 2026 Peptide Research Update

ADA 2026 Day 3 Context: The Triple Data Day

Day 3 of the American Diabetes Association's 2026 Scientific Sessions (June 7, New Orleans) delivered three distinct but strategically connected data packages. Eli Lilly presented full TRIUMPH-4 Phase 3 data — the first randomized controlled trial to demonstrate that a pharmacotherapy can simultaneously achieve bariatric-level weight loss and clinically meaningful musculoskeletal pain relief in obesity patients with knee osteoarthritis. Novo Nordisk presented the complete Phase 2 T2D dataset for zenagamtide (amycretin), confirming that the unimolecular GLP-1/amylin agonist matches leading diabetes drugs on glycemic endpoints while adding substantial weight loss — triggering a Phase 3 T2D program for H2 2026. Separately, Novo Nordisk's CagriSema functional brain imaging study provided the mechanistic explanation for why GLP-1/amylin combination therapy may outperform GLP-1 monotherapy: distinct neural circuit engagement in regions governing appetite regulation and food reward.

TRIUMPH-4 Full Data: Retatrutide Sets the Obesity-Osteoarthritis Benchmark — 28.7% Weight Loss, 75.8% Knee Pain Reduction

The TRIUMPH-4 Phase 3 trial randomized adults with BMI ≥27 and confirmed knee osteoarthritis to once-weekly subcutaneous retatrutide (4 mg, 9 mg, 12 mg) or placebo over 68 weeks. Co-primary endpoints were percent change in body weight and change in WOMAC knee pain score at week 68. All dose arms met co-primary and key secondary endpoints. The 12 mg dose delivered 28.7% mean weight loss (vs 3.3% placebo) — the highest body weight reduction reported across all retatrutide Phase 3 programs. Mean absolute weight lost in the 12 mg arm was 71.2 lbs — representing a uniquely high absolute weight reduction driven partly by higher baseline body weights in OA populations. Knee pain outcomes were equally striking: WOMAC pain scores declined by 75.8% from baseline (4.5-point reduction vs 0.5-point placebo), with 12.0% of retatrutide 12 mg participants completely free of knee pain at week 68 vs 4.2% placebo. Systolic blood pressure fell by 14 mmHg in the 12 mg arm. Physical function scores improved significantly across all dose levels. The TRIUMPH-4 data establish a new benchmark for pharmacotherapy in musculoskeletal comorbidities of obesity — no prior drug trial in the obesity-OA space has documented simultaneous >25% weight reduction and >70% pain relief.

What TRIUMPH-4 Means for Retatrutide's Regulatory Path and the OA Market

TRIUMPH-4 is the second completed Phase 3 trial for retatrutide (after TRIUMPH-1) and the first to demonstrate an obesity drug's impact on knee osteoarthritis as a co-primary endpoint rather than an exploratory one. This matters because FDA has historically required co-primary OA data — not just weight-mediated pain improvement — to grant a musculoskeletal indication. By designing TRIUMPH-4 with WOMAC as a co-primary endpoint in a dedicated OA population, Eli Lilly appears to have laid the groundwork for a potential supplemental indication alongside the planned Q4 2026 obesity NDA. The addressable OA market is massive: an estimated 32.5 million US adults have osteoarthritis, and knee OA is one of the most common weight-related comorbidities driving demand for GLP-1 therapies. Six additional TRIUMPH trials are expected to report results throughout 2026, including TRIUMPH-2 (obesity + T2D), TRIUMPH-3 (established CVD), and TRIUMPH-MASH (metabolic liver disease).

Zenagamtide ADA 2026 Phase 2 T2D Data: 14.6% Weight Loss, 89% A1C Target — Phase 3 T2D Program Greenlit

Novo Nordisk's Phase 2 dose-finding study for zenagamtide in type 2 diabetes enrolled 262 adults with T2D inadequately controlled on metformin (±SGLT2 inhibitor), with baseline A1C between 7.0% and 10.0%. Six subcutaneous doses (0.4–40 mg once-weekly) were tested vs placebo over 36 weeks. The 40 mg dose — the highest tested — achieved 14.6% mean weight loss alongside a 1.71 percentage-point HbA1c reduction. At the 40 mg dose, 89% of participants achieved the ADA's general A1C target of below 7%, and 77.8% reached the tighter ≤6.5% target. All six doses met the primary endpoint of A1C reduction; weight reduction endpoints were met at doses ≥1.5 mg. The T2D dataset complements the existing obesity Phase 1b/2a data (22% weight loss at 36 weeks, published in The Lancet 2025), establishing zenagamtide across both primary metabolic indications. Novo Nordisk confirmed Phase 3 T2D program initiation in H2 2026 alongside the ongoing REDEFINE obesity Phase 3. Zenagamtide now becomes the only unimolecular GLP-1/amylin agonist with Phase 2 evidence in both obesity and type 2 diabetes.

CagriSema Brain Imaging: The First fMRI Evidence for Dual GLP-1/Amylin Appetite Circuit Engagement

A separate Novo Nordisk presentation at ADA 2026 provided functional brain imaging data from CagriSema (cagrilintide + semaglutide 2.4 mg), adding a mechanistic dimension to the combination's 22.7% weight loss results. The study used functional MRI to examine appetite and food reward circuit activation in people with overweight/obesity treated with CagriSema versus placebo. The imaging data demonstrate that combined GLP-1 and amylin receptor agonism engages distinct neural substrates — including the hypothalamic arcuate nucleus, area postrema, and nucleus accumbens — in ways that GLP-1 monotherapy alone does not fully activate. This neuroimaging evidence is significant for two reasons: first, it provides a biological mechanism for why CagriSema produces greater weight loss than semaglutide alone (18% + semaglutide component vs semaglutide 2.4 mg monotherapy data); second, it supports the thesis that zenagamtide — which embeds the same dual mechanism into a single molecule — may replicate or exceed these neural satiety effects at lower doses. The brain activity data represent the first direct fMRI evidence of amylin receptor agonism modifying appetite circuits in an obesity population.

ADA 2026 Landscape Synthesis: What Three Days of Data Tell Us About the 2026-2027 Obesity Pipeline

ADA 2026 (June 5–8) has now delivered at least seven major peptide data packages across three days: TRIUMPH-1 full data + TRANSCEND-T2D-1 full data (Day 1), petrelintide ZUPREME-1 cardiometabolic secondaries + DA-1726 three posters (Day 2), and TRIUMPH-4 + zenagamtide T2D Phase 2 + CagriSema brain imaging (Day 3). The conference has established several durable 2026 narratives: (1) Triple agonism (retatrutide) sets the efficacy ceiling above 28% weight loss across multiple organ systems; (2) Unimolecular dual agonism (zenagamtide, petrelintide) is now validated in both obesity and T2D, opening two-indication regulatory paths simultaneously; (3) Mechanistic imaging data (CagriSema brain study) is becoming a standard component of obesity trial packages, likely influencing Phase 3 design for next-generation compounds; (4) Musculoskeletal indications (OA, back pain) are emerging as legitimate secondary endpoints that may influence prescribing and payer decisions. The next major catalysts are ADA Day 4 (June 8) wrap-up data, the FDA PCAC peptide review (July 23–24), taldefgrobep Phase 2 obesity data (H2 2026), and the survodutide FDA decision (Q3 2026).

Citations

1. [1] Source
2. [2] Source
3. [3] Source
4. [4] Source
5. [5] Source
6. [6] Source
7. [7] Source
8. [8] Source

Related Articles

research-summaries

ADA 2026 Day 2: Petrelintide Full ZUPREME-1 Data Confirms Cardiometabolic Benefits and Phase 3 Path, DA-1726 Posts Three Abstracts — June 6, 2026 Peptide Research Update

ADA 2026 Day 2 in New Orleans brings full ZUPREME-1 body composition and cardiometabolic data for petrelintide (Zealand/Roche) — confirming hsCRP reductions of 17–41%, triglyceride reductions of 12–21%, and waist circumference improvements of up to 10.8 cm, all with placebo-like tolerability — alongside three MetaVia DA-1726 late-breaking poster abstracts covering final MAD data, lean mass preservation, and direct hepatic FibroScan endpoints.

PepTracker Pro Research Team

June 6, 2026 8 min read min read

ADA-2026ADA-Scientific-SessionsNew-Orleans

Read